These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161 [TBL] [Abstract][Full Text] [Related]
7. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565 [TBL] [Abstract][Full Text] [Related]
8. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251 [TBL] [Abstract][Full Text] [Related]
10. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704 [TBL] [Abstract][Full Text] [Related]
11. Parametric Net Influx Rate Images of Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716 [No Abstract] [Full Text] [Related]
12. Regulatory Requirements for PET Drug Production. Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057 [TBL] [Abstract][Full Text] [Related]
13. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441 [TBL] [Abstract][Full Text] [Related]
14. Sensitivity Comparison of Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855 [TBL] [Abstract][Full Text] [Related]